INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Background Blood-based biomarkers of Alzheimer's disease (AD) have become
increasingly important as scalable tools for diagnosis and determining clinical trial eligibility …

Abstract Objective Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical
Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is …

Recently, low-sensitive plasma assays have been replaced by new ultra-sensitive assays
such as single molecule enzyme-linked immunosorbent assay (Simoa), the Mesoscale …

Introduction Phosphorylated tau (p‐tau) in cerebrospinal fluid (CSF) is an established
Alzheimer's disease (AD) biomarker. Novel immunoassays targeting N‐terminal and mid …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in
memory clinic populations are needed to understand possible differences. Methods In the …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are
two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD) …